Merz Therapeutics acquires two Parkinson's, MS medicines from Acorda for $185M under US Bankruptcy Code, expected to close in June 2024.
Merz Therapeutics, a subsidiary of Merz Group, has agreed to acquire two commercial medicines from Acorda Therapeutics for $185 million in a court-structured 363 sale process under the US Bankruptcy Code. The medicines treat OFF phases of Parkinson's disease and gait disorders in multiple sclerosis. The deal is expected to close in June 2024, pending court approval. The acquisition aligns with Merz Therapeutics' focus on patient care and innovative therapies.
April 01, 2024
8 Articles